title: Safeguarding patients in clinical trials with high mortality rates.
authors.affiliation: Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA. freemanb@msnotes.wustl.edu
authors.forename: B D
authors.initials: BD
authors.lastname: Freeman
authors.forename: R L
authors.initials: RL
authors.lastname: Danner
authors.forename: S M
authors.initials: SM
authors.lastname: Banks
authors.forename: C
authors.initials: C
authors.lastname: Natanson
mesh_terms: D001241:Aspirin / Q000031:analogs & derivatives / Q000627:therapeutic use; D001802:Blood Substitutes / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000592:standards*; D016638:Critical Illness / Q000401:mortality* / Q000628:therapy*; D006454:Hemoglobins / Q000627:therapeutic use; D019382:Human Growth Hormone / Q000627:therapeutic use; D006801:Humans; D012771:Shock, Hemorrhagic / Q000188:drug therapy; D012772:Shock, Septic / Q000188:drug therapy; D019323:omega-N-Methylarginine / Q000627:therapeutic use
chemical_list: D001802:Blood Substitutes; D006454:Hemoglobins; D019382:Human Growth Hormone; D019323:omega-N-Methylarginine; C083478:diaspirin-cross-linked hemoglobin; D001241:Aspirin